# Phenotyping of human immune responses to dengue vaccination and infection in Argentina

> **NIH NIH U19** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $400,000

## Abstract

Latin America is currently experiencing the largest outbreak of dengue in its history. In the first
months of 2024, there have been a total of 4,820,955 reported cases of dengue. This number is
more than four times more than the number of cases reported during the same period in 2023,
which itself was a record year with over 4.5 million cases. In the case of Argentina, mainly two
serotypes are currently co-circulating (DENV2 58% and DENV1 42%). The recently approved
Takeda Dengue vaccine (Qdenga) is now widely offered in Argentina. The Qdenga Dengue
vaccine protects against all four serotypes of the dengue virus. Two vaccine doses are
administered over a three-months interval.We propose to study the immune responses elicited
by the Qdenga Dengue vaccine in naïve and previously infected individuals before and after the
first and second vaccine doses. We will leverage approaches currently used in VIVA (e.g.,
multiplex chemokine/cytokine measurements [Luminex], high-dimensional cellular responses
[AURORA flow cytometry], transcriptome analysis) to analyze responses to dengue vaccinations
taking advantage of the introduction of dengue vaccines for the first time in Argentina. In addition,
we will compare the results of our current studies with samples from the NIH tetravalent vaccine
trials in Thailand (provided by Dr. Anna Durbin) to the data generated using samples from Qdenga
vaccinees in Argentina. Lastly, we will recapitulate and dissect the Qdenga vaccine responses
using the tonsillar histocultures model system.

## Key facts

- **NIH application ID:** 11110679
- **Project number:** 3U19AI168631-03S2
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Ana Fernandez-Sesma
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $400,000
- **Award type:** 3
- **Project period:** 2022-03-22 → 2027-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11110679

## Citation

> US National Institutes of Health, RePORTER application 11110679, Phenotyping of human immune responses to dengue vaccination and infection in Argentina (3U19AI168631-03S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11110679. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*